Canton Strategic sells its biotechnology research and development division Gravitas, shifting focus to digital business in the financial market

According to PRNewswire, Nasdaq-listed company Canton Strategic Holdings announced that it has completed the sale of its biotechnology research and development department, Gravitas Life Sciences, to Gravitas Collective Corp. The transaction was unanimously approved by the company's board of directors and was officially completed on July 17, 2026.

This sale marks the company's further transformation into an operational enterprise focused on driving the digitization of traditional financial markets around the Canton Network, promoting asset tokenization and the digitization process of financial markets, as well as financial infrastructure business.